Indaptus Therapeutics Q3 net loss narrows as R&D costs fall

By Reuters News


Overview

  • US biotechnology firm's Q3 net loss narrowed sharply from prior year

  • Research and development expenses fell 82% due to lower clinical costs and reduced headcount

  • Company completed $24 mln private placement to fund research and working capital


Outlook

  • Company intends to use recent funding for R&D and early-stage neurotechnology device research

  • Indaptus expects current liquidity to fund anticipated operating and capital expenditures


Result Drivers

  • R&D COST CUTS - Research and development expenses fell sharply due to lower clinical costs from Decoy20 Phase 1 study wind-down and reduced headcount

  • ADMINISTRATIVE SAVINGS - General and administrative expenses declined due to lower management transition costs and payroll reductions

  • LIQUIDITY - As of September 30, the company had $26.6 million in cash and cash equivalents and $4.0 million in short-term investments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss Per Share

$0.01


Reuters Recommended Reads

  • Nov 12 - MDxHealth's Q3 revenue misses expectations due to disrupted commercial execution

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.